Flash Finance

Sigachi Industries LimitedSIGACHICorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹27.52
MCap ₹1,053 Cr · P/E 40.0
Sigachi Industries Limited — Stock analysis & AI research Sigachi Industries Limited — Multibagger AI analysis Sigachi Industries Limited — Seasonality — best & worst months Sigachi Industries Limited — Technical setup — score, trend, support & resistance Sigachi Industries Limited — Live exchange announcements
📈 Bollinger Squeeze Stocks📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹121 Cr
Sales · Jun 2026
-5.4% YoY
₹17 Cr
Operating Profit · Jun 2026
-31.5% YoY
13.6%
OPM % · Jun 2026
-27.7% YoY
₹8 Cr
Net Profit · Jun 2026
+108.1% YoY
₹0.18
EPS · Jun 2026
+106.8% YoY

📝 Sigachi Industries Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sigachi Industries Limited reported revenue of ₹121 crore for the quarter ended June 2026 (Q1 FY27), down 5.4% from ₹128 crore in the same quarter last year, and down 0.5% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹8 crore from a net loss of ₹101 crore a year earlier. Earnings per share (EPS) came in at ₹0.18.

Operating profit stood at ₹17 crore — an operating margin (OPM) of 13.6%, compared with 18.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sigachi Industries Limited posted revenue of ₹478 crore, a decline of 2.1% over FY25, with a net loss of ₹83 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹471 crore with a net profit of ₹26 crore.

Valuation snapshot

At the current price of ₹27.52, SIGACHI has a market capitalisation of ₹1,053 crore and a trailing P/E of about 40.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 36.69%, foreign institutional investors (FIIs) 1.25%, public shareholders 62.05% of Sigachi Industries Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,053 Cr
Current Price ?
₹27.5
P/E ?
40.01above ind
Industry P/E ?
37.20
P/B ?
2.02
P/S ?
2.24
P/FCF ?
-28.45
Enterprise Value ?
₹1,192 Cr
EV/EBITDA ?
25.82
PEG ?
N/A
Earnings Yield ?
2.4%
Dividend Yield ?
0.36%
Profitability & Returns
Sales (TTM) ?
₹471 Cr
OPM ?
9.8%
Profit after tax (TTM) ?
₹26 Cr
EPS (TTM) ?
₹0.69
ROCE ?
6.0%
ROE ?
5.0%
ROA ?
3.1%
Growth
Sales — latest qtr ?
₹121 Cr
PAT — latest qtr ?
₹8 Cr
YoY qtr sales growth ?
-5.4%
YoY qtr profit growth ?
108.1%
Sales growth (3y) ?
17%
Sales growth (5y) ?
20%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹139 Cr
Debt to Equity ?
0.27
Interest Coverage ?
2.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
36.69%
Change in promoter holding ?
-7.45%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.0%
Return 6 months ?
17.9%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 6572859911110496125139128128110117122121 -5.4% -0.5%
Operating Profit 1312162123162117332924861617 -31.5% +0.6%
Other Income 1221272152247001 -74.6% +377.6%
Interest 111223324333343 -8.9% -30.4%
Depreciation 222333335554454 -6.6% -3.4%
Profit Before Tax 12101518201716272723-1017-2810 +110.0% +30.7%
Net Profit 971115161513212116-10111-088 +108.1% +6.5%
EPS 3.032.383.544.930.510.480.400.660.650.36-2.630.280.010.200.18 +106.8% -10.0%
OPM % 20.6% 16.8% 19.3% 21.6% 20.4% 15.7% 22.0% 13.8% 23.8% 22.3% 18.8% 6.8% 4.9% 13.5% 13.6% -27.7% +0.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹488 Cr ₹478 Cr ₹471 Cr -2.1%
Operating Profit ₹100 Cr ₹54 Cr ₹46 Cr -46.2%
OPM % 20.48% 11.25% 9.80% -45.1%
NPM % 14.43% -17.33% 5.59% -220.1%
Other Income ₹21 Cr ₹12 Cr ₹9 Cr -42.6%
Depreciation ₹16 Cr ₹18 Cr ₹17 Cr +11.5%
Interest ₹12 Cr ₹14 Cr ₹14 Cr +11.9%
EBIT ₹84 Cr ₹36 Cr ₹29 Cr -57.1%
PBT ₹92 Cr ₹-88 Cr ₹23 Cr -195.0%
Tax ₹22 Cr ₹-2 Cr ₹0 Cr -108.5%
Net Profit ₹70 Cr ₹-83 Cr ₹26 Cr -217.5%
EPS ₹2.07 ₹-2.14 ₹0.67 -203.4%
Material Cost ₹238 Cr ₹124 Cr ₹120 Cr -48.1%
Employee Cost ₹74 Cr ₹43 Cr ₹52 Cr -41.3%
Extraordinary Items — ₹-122 Cr ₹-1 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CWIP 3597931 +244.4%
Equity Capital 31333838 +0.0%
Reserves 238397563484 -14.0%
Borrowings 68151142139 -2.1%
Other Liabilities 37113103180 +74.8%
Total Liabilities 374694846841 -0.6%
Fixed Assets 122254370325 -12.2%
Investments 0000 —
Other Assets 216342467485 +3.9%
Total Assets 374694846841 -0.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2913274 -85.2%
Cash from Investing Activity -92-161-93-53 +43.0%
Cash from Financing Activity 26172812 -97.5%
Net Cash Flow -372415-46 -406.7%
Free Cash Flow -72-72-16-37 -131.2%
CFO/OP 71%29%41%27% -34.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 97137137171 +24.8%
Inventory Days 123132155108 -30.3%
Days Payable 55905987 +47.5%
Cash Conversion Cycle 165180234193 -17.5%
Working Capital Days 856310371 -31.1%
ROCE % 20%17%16%6% -62.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 44.14%40.48%39.70%36.69%36.69% +0.0%
FIIs 2.89%3.10%3.33%1.31%1.25% -4.6%
Public 52.97%56.41%56.97%62.01%62.05% +0.1%
No. of Shareholders 1,51,2062,05,2661,94,7771,94,5591,88,986 -2.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 SIGACHI Sigachi Industries ₹28.58 1,093 49.2 471 26 9.8% 5.6% -2.1% -217.5% -5.4% 108.1%
❓ Frequently asked questions
What was Sigachi Industries Limited's revenue in Q1 FY27?
Sigachi Industries Limited reported revenue of ₹121 crore for the quarter ended June 2026 (Q1 FY27), down 5.4% from ₹128 crore in the same quarter last year, and down 0.5% sequentially over the March 2026 quarter.
What was Sigachi Industries Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹8 crore from a net loss of ₹101 crore a year earlier. Earnings per share (EPS) came in at ₹0.18.
What is SIGACHI's market capitalisation and P/E ratio?
At the current price of ₹27.52, SIGACHI has a market capitalisation of ₹1,053 crore and a trailing P/E of about 40.0.
Who owns Sigachi Industries Limited? (shareholding pattern)
As of Jun 2026, promoters held 36.69%, foreign institutional investors (FIIs) 1.25%, public shareholders 62.05% of Sigachi Industries Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI